Cargando…
Polyphenols as Promising Drugs against Main Breast Cancer Signatures
Breast cancer is one of the most common neoplasms worldwide, and in spite of clinical and pharmacological advances, it is still a clinical problem, causing morbidity and mortality. On the one hand, breast cancer shares with other neoplasms some molecular signatures such as an imbalanced redox state,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745498/ https://www.ncbi.nlm.nih.gov/pubmed/29112149 http://dx.doi.org/10.3390/antiox6040088 |
_version_ | 1783288916310228992 |
---|---|
author | Losada-Echeberría, María Herranz-López, María Micol, Vicente Barrajón-Catalán, Enrique |
author_facet | Losada-Echeberría, María Herranz-López, María Micol, Vicente Barrajón-Catalán, Enrique |
author_sort | Losada-Echeberría, María |
collection | PubMed |
description | Breast cancer is one of the most common neoplasms worldwide, and in spite of clinical and pharmacological advances, it is still a clinical problem, causing morbidity and mortality. On the one hand, breast cancer shares with other neoplasms some molecular signatures such as an imbalanced redox state, cell cycle alterations, increased proliferation and an inflammatory status. On the other hand, breast cancer shows differential molecular subtypes that determine its prognosis and treatment. These are characterized mainly by hormone receptors especially estrogen receptors (ERs) and epidermal growth factor receptor 2 (HER2). Tumors with none of these receptors are classified as triple negative breast cancer (TNBC) and are associated with a worse prognosis. The success of treatments partially depends on their specificity and the adequate molecular classification of tumors. New advances in anticancer drug discovery using natural compounds have been made in the last few decades, and polyphenols have emerged as promising molecules. They may act on various molecular targets because of their promiscuous behavior, presenting several physiological effects, some of which confer antitumor activity. This review analyzes the accumulated evidence of the antitumor effects of plant polyphenols on breast cancer, with special attention to their activity on ERs and HER2 targets and also covering different aspects such as redox balance, uncontrolled proliferation and chronic inflammation. |
format | Online Article Text |
id | pubmed-5745498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-57454982018-01-02 Polyphenols as Promising Drugs against Main Breast Cancer Signatures Losada-Echeberría, María Herranz-López, María Micol, Vicente Barrajón-Catalán, Enrique Antioxidants (Basel) Review Breast cancer is one of the most common neoplasms worldwide, and in spite of clinical and pharmacological advances, it is still a clinical problem, causing morbidity and mortality. On the one hand, breast cancer shares with other neoplasms some molecular signatures such as an imbalanced redox state, cell cycle alterations, increased proliferation and an inflammatory status. On the other hand, breast cancer shows differential molecular subtypes that determine its prognosis and treatment. These are characterized mainly by hormone receptors especially estrogen receptors (ERs) and epidermal growth factor receptor 2 (HER2). Tumors with none of these receptors are classified as triple negative breast cancer (TNBC) and are associated with a worse prognosis. The success of treatments partially depends on their specificity and the adequate molecular classification of tumors. New advances in anticancer drug discovery using natural compounds have been made in the last few decades, and polyphenols have emerged as promising molecules. They may act on various molecular targets because of their promiscuous behavior, presenting several physiological effects, some of which confer antitumor activity. This review analyzes the accumulated evidence of the antitumor effects of plant polyphenols on breast cancer, with special attention to their activity on ERs and HER2 targets and also covering different aspects such as redox balance, uncontrolled proliferation and chronic inflammation. MDPI 2017-11-07 /pmc/articles/PMC5745498/ /pubmed/29112149 http://dx.doi.org/10.3390/antiox6040088 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Losada-Echeberría, María Herranz-López, María Micol, Vicente Barrajón-Catalán, Enrique Polyphenols as Promising Drugs against Main Breast Cancer Signatures |
title | Polyphenols as Promising Drugs against Main Breast Cancer Signatures |
title_full | Polyphenols as Promising Drugs against Main Breast Cancer Signatures |
title_fullStr | Polyphenols as Promising Drugs against Main Breast Cancer Signatures |
title_full_unstemmed | Polyphenols as Promising Drugs against Main Breast Cancer Signatures |
title_short | Polyphenols as Promising Drugs against Main Breast Cancer Signatures |
title_sort | polyphenols as promising drugs against main breast cancer signatures |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745498/ https://www.ncbi.nlm.nih.gov/pubmed/29112149 http://dx.doi.org/10.3390/antiox6040088 |
work_keys_str_mv | AT losadaecheberriamaria polyphenolsaspromisingdrugsagainstmainbreastcancersignatures AT herranzlopezmaria polyphenolsaspromisingdrugsagainstmainbreastcancersignatures AT micolvicente polyphenolsaspromisingdrugsagainstmainbreastcancersignatures AT barrajoncatalanenrique polyphenolsaspromisingdrugsagainstmainbreastcancersignatures |